A Phase 2 interventional study of Glucagon in Type 1 Diabetes, sponsored by St. Olavs Hospital. Terminated at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by St. Olavs Hospital · Phase 2, Interventional, and Treatment
The investigators will study the effect of microdoses of glucagon at the site of subcutaneous insulin injection. The investigators have unpublished data from anesthetized pigs indicating a major enhancement of insulin absorption.
People with type 1 diabetes will come fasting in the morning to the research facility on two separate days. Both days participants will have a breakfast of their own choice and their regular dose of meal insulin injected. Lyumjev will be used. Frequently collected blood sampled will be analysed for glucose, insulin and glucagon for 3.5 hours. The procedures will be exactly the same both days except that on one of the days they will be randomised to a small dose of glucagon that will be injected at exactly the same site as Lyumjev insulin is injected.
10,923 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.
This study's enrollment of 9 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →St. Olavs Hospital is the lead sponsor of 165 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
1: Type 1 diabetes for at least 1 year. 2. Age 18 - 70 years. 3. Last known HbA1c \<86 mmol/mol. 4. Treated with continuous subcutaneous insulin infusion (CSII) by an insulin pump or multiple daily insulin injections (MDII).
Exclusion Criteria:
Micro dose of glucagon is aded at the insulin injection site
Drug: Glucagon
Insulin injected without any glucagon
A micro-dose of glucagon is added exactly at the same site as insulin is injected.
Area under the glucose curve
The area under the glucose curve (change from baseline glucose level)
Time frame: From time 0 minutes to time 60 minutes
Area under glucose curve
The area under the glucose curve (change from baseline glucose level)
Time frame: Any other time span from time 0 minutes to time 180 minutes
Area under insulin curve
The area under the insulin curve
Time frame: Any time frame from time 0 minutes to time 180 minutes
Area under glucagon curve
The area under the glucagon curve
Time frame: Any time frame from time 0 minutes to time 180 minutes
Pharmacokinetics of insulin
Time to Cmax.
Time frame: Start from time 0
Pharmacokinetics of glucagon
Time to Cmax
Time frame: Start from time 0
Plan to share: No
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Olavs Hospital